Cancer

Marius Pharmaceuticals Receives Sixth U.S. Patent Allowance for KYZATREX® (testosterone undecanoate) CIII Capsules Extending Coverage to 2040

RALEIGH, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone…

7 months ago

Immunotherapeutic Targets for Recurrent Medulloblastoma Receives $85K Grant from Brain Cancer Canada

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to award $85,000 to a groundbreaking research project…

7 months ago

Flare Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to…

7 months ago

HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design

The company has developed the first-ever platform to unlock precision control over glycans, essential sugar molecules found on the surface…

7 months ago

Alpha Tau to Present at Jefferies Global Healthcare Conference

JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

7 months ago

iTeos Therapeutics Announces Its Intention to Wind Down Operations

- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term…

7 months ago

Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting

Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T-cell lymphomaPHILADELPHIA, May 28, 2025…

7 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty…

7 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and…

7 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics…

7 months ago